MedTrace Logo

Multi-modal Neuroimaging in Alzheimer's Disease IMAP+

NCT01638949 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2026-04-02

No results posted yet for this study

Summary

Alzheimer's disease (AD) is a major public health problem due to its socio-economic weight. An early diagnosis of AD is urgently needed as it would constitute a determinant breakthrough from a social, financial and research standpoints. Therefore, the investigators need predictive markers of AD, and neuroimaging is a particularly promising tool, especially when using complementary neuroimaging techniques and a longitudinal design, allowing to assess the relationships between the different biomarkers of the disease, their dynamic and their chronology.

Conditions

Interventions

BEHAVIORAL

Memory assessment

Neuropsycological tests including clinical and original tests to compare differences between each populations.

BIOLOGICAL

Circulating biomarkers measure

ELISA tests from blood samples to compare differences between each populations.

GENETIC

ApoE4

Evaluation of apolipoprotein E polymorphism as a risk factor.

OTHER

Brain imaging examination MRI and PET examinations

Structural and functional MRI FDG-PET to compare differences between each populations.

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Vincent de La Sayette, MD · University Hospital, Caen

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2020-01-20
Completion
2022-09-20

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01638949 on ClinicalTrials.gov